Ar­ray shows off the pos­i­tive BEA­CON CRC da­ta that helped spur Pfiz­er's $11.4B buy­out of­fer

In­ves­ti­ga­tors took cen­ter stage at a sci­en­tif­ic con­fer­ence to­day to tout the pos­i­tive da­ta from the BEA­CON CRC tri­al of Ar­ray’s BRAF/MEK triplet for drug re­sis­tant colon can­cer that played a key role in at­tract­ing Pfiz­er’s $11.4 bil­lion buy­out bid.

The FDA had al­ready stamped its break­through des­ig­na­tion on the triple ther­a­py of (Braftovi) en­co­rafenib in com­bi­na­tion with (Mek­tovi) binime­tinib and ce­tux­imab be­fore Pfiz­er ex­ecs were pro­vid­ed a glimpse of the top-line re­sults in May — whet­ting their ap­petite for the ac­qui­si­tion dur­ing the fi­nal days of their ne­go­ti­a­tions. That’s when they learned that the triplet scored a me­di­an over­all sur­vival rate of 9 months among drug re­sis­tant pa­tients with BRAF V600E-mu­tat­ed cas­es of col­orec­tal can­cer com­pared to 5.4 months for the stan­dard of care. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER